Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter inspIRE Study

M. Duytschaever, T. De Potter, M. Grimaldi, A. Anic, J. Vijgen, P. Neuzil, H. Van Herendael, A. Verma, A. Skanes, D. Scherr, H. Pürerfellner, G. Rackauskas, P. Jaïs, VY. Reddy, inspIRE Trial Investigators

. 2023 ; 16 (3) : e011780. [pub] 20230203

Jazyk angličtina Země Spojené státy americké

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003937

BACKGROUND: The inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed Field Ablation [PFA] System With Irreversible Electroporation [IRE]) evaluated safety and effectiveness of a fully integrated biphasic pulsed field ablation (PFA) system with a variable-loop circular catheter for the treatment of drug-refractory paroxysmal atrial fibrillation. METHODS: Subjects underwent pulmonary vein (PV) isolation with the PFA system, using at least 12 applications per vein; adenosine/isoproterenol was administered to confirm entrance block. Wave I assessed initial safety, including for esophageal lesions, silent cerebral lesions, and PV stenosis. Wave II (pivotal phase) tested (1) primary safety, incidence of early-onset primary adverse events, and (2) primary effectiveness, confirmed PV isolation with freedom from documented atrial arrhythmia at 12 months. The study design specified an interim analysis to determine early success once 30 subjects reached the 12-month follow-up and all subjects reached 3-month follow-up. RESULTS: Across 13 centers in Europe/Canada, 226 subjects were enrolled, met criteria for safety and effectiveness evaluations, and received PFA (Wave I, 40; Wave II, 186). Wave I demonstrated no esophageal thermal lesions or PV stenosis. Among 39 subjects with cerebral magnetic resonance imaging, silent cerebral lesions were detected in 4 of the first 6 subjects, after which workflow enhancements, including a 10-second pause between PFA applications, were implemented; subsequently, only 4 of 33 subjects had silent cerebral lesions. In the Wave II phase, no primary adverse events were reported. Upon declaring early success, 83 subjects reached 12-month follow-up. With 100% entrance block, PV isolation without acute reconnection was achieved in 97.1% of targeted veins. For Wave II, the primary effectiveness end point per Kaplan-Meier at the time of interim analysis was 70.9%; 12-month freedom from symptomatic atrial fibrillation/atrial flutter/atrial tachycardia recurrence and repeat ablation was 78.9% and 92.3%, respectively. Total procedure and transpired PFA times were 70.1±27.7 and 26.7±14.0 minutes, respectively. CONCLUSIONS: The inspIRE trial confirmed the safety and effectiveness of the novel mapping-integrated PFA system. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; unique identifier: NCT04524364.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003937
003      
CZ-PrNML
005      
20230425141008.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCEP.122.011780 $2 doi
035    __
$a (PubMed)36735937
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Duytschaever, Mattias $u Department of Cardiology, AZ Sint Jan, Brugge, Belgium (M.D.) $1 https://orcid.org/0000000184510013 $7 xx0257832
245    10
$a Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter inspIRE Study / $c M. Duytschaever, T. De Potter, M. Grimaldi, A. Anic, J. Vijgen, P. Neuzil, H. Van Herendael, A. Verma, A. Skanes, D. Scherr, H. Pürerfellner, G. Rackauskas, P. Jaïs, VY. Reddy, inspIRE Trial Investigators
520    9_
$a BACKGROUND: The inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed Field Ablation [PFA] System With Irreversible Electroporation [IRE]) evaluated safety and effectiveness of a fully integrated biphasic pulsed field ablation (PFA) system with a variable-loop circular catheter for the treatment of drug-refractory paroxysmal atrial fibrillation. METHODS: Subjects underwent pulmonary vein (PV) isolation with the PFA system, using at least 12 applications per vein; adenosine/isoproterenol was administered to confirm entrance block. Wave I assessed initial safety, including for esophageal lesions, silent cerebral lesions, and PV stenosis. Wave II (pivotal phase) tested (1) primary safety, incidence of early-onset primary adverse events, and (2) primary effectiveness, confirmed PV isolation with freedom from documented atrial arrhythmia at 12 months. The study design specified an interim analysis to determine early success once 30 subjects reached the 12-month follow-up and all subjects reached 3-month follow-up. RESULTS: Across 13 centers in Europe/Canada, 226 subjects were enrolled, met criteria for safety and effectiveness evaluations, and received PFA (Wave I, 40; Wave II, 186). Wave I demonstrated no esophageal thermal lesions or PV stenosis. Among 39 subjects with cerebral magnetic resonance imaging, silent cerebral lesions were detected in 4 of the first 6 subjects, after which workflow enhancements, including a 10-second pause between PFA applications, were implemented; subsequently, only 4 of 33 subjects had silent cerebral lesions. In the Wave II phase, no primary adverse events were reported. Upon declaring early success, 83 subjects reached 12-month follow-up. With 100% entrance block, PV isolation without acute reconnection was achieved in 97.1% of targeted veins. For Wave II, the primary effectiveness end point per Kaplan-Meier at the time of interim analysis was 70.9%; 12-month freedom from symptomatic atrial fibrillation/atrial flutter/atrial tachycardia recurrence and repeat ablation was 78.9% and 92.3%, respectively. Total procedure and transpired PFA times were 70.1±27.7 and 26.7±14.0 minutes, respectively. CONCLUSIONS: The inspIRE trial confirmed the safety and effectiveness of the novel mapping-integrated PFA system. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; unique identifier: NCT04524364.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x diagnóza $x chirurgie $x etiologie $7 D001281
650    _2
$a stenóza $x etiologie $x chirurgie $7 D003251
650    _2
$a výsledek terapie $7 D016896
650    _2
$a katétry $7 D057785
650    12
$a venae pulmonales $x chirurgie $7 D011667
650    12
$a stenóza plicní žíly $x etiologie $7 D000071078
650    12
$a katetrizační ablace $x škodlivé účinky $x metody $7 D017115
650    _2
$a recidiva $7 D012008
651    _2
$a Evropa $7 D005060
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a De Potter, Tom $u Onze Lieve Vrouwziekenhuis Hospital, Dienst Cardiologie, Aalst, Belgium (T.D.P.) $1 https://orcid.org/000000031424114X
700    1_
$a Grimaldi, Massimo $u Ospedale Generale Regionale "F. Miulli" UOC Cardiologia, Acquaviva delle Fonti, Bari, Italy (M.G.) $1 https://orcid.org/0000000293478884
700    1_
$a Anic, Ante $u Cardiovascular Diseases, University Hospital Center Split, Croatia (A.A.) $1 https://orcid.org/0000000268643999
700    1_
$a Vijgen, Johan $u Cardiology Department, Jessa Hospitals, Hasselt, Belgium (J.V.)
700    1_
$a Neuzil, Petr $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic (P.N., V.Y.R.) $1 https://orcid.org/0000000343348165
700    1_
$a Van Herendael, Hugo $u Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium (H.V.H.)
700    1_
$a Verma, Atul $u McGill University Health Centre, McGill University, Montréal, Canada (A.V.) $1 https://orcid.org/0000000210209727
700    1_
$a Skanes, Allan $u Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada (A.S.)
700    1_
$a Scherr, Daniel $u Division of Cardiology, University Heart Center, Medical University Graz, Austria (D.S.)
700    1_
$a Pürerfellner, Helmut $u Department für Kardiologie und Elektrophysiologie, Akademisches Lehrkrankenhaus, Ordensklinikum Linz GmbH/Elisabethinen, Austria (H.P.) $1 https://orcid.org/0000000289658495
700    1_
$a Rackauskas, Gediminas $u Department of Cardiovascular Diseases, Centre for Cardiology and Angiology, Vilnius University, Lithuania (G.R.) $1 https://orcid.org/0000000332724380
700    1_
$a Jaïs, Pierre $u Centre Hospitalier Universitaire de Bordeaux (Main), Pesac, France (P.J.) $1 https://orcid.org/0000000247007811
700    1_
$a Reddy, Vivek Y $u Cardiovascular Diseases, University Hospital Center Split, Croatia (A.A.) $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic (P.N., V.Y.R.) $1 https://orcid.org/0000000256384993
710    2_
$a inspIRE Trial Investigators
773    0_
$w MED00159578 $t Circulation. Arrhythmia and electrophysiology $x 1941-3084 $g Roč. 16, č. 3 (2023), s. e011780
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36735937 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141004 $b ABA008
999    __
$a ok $b bmc $g 1924541 $s 1190146
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 16 $c 3 $d e011780 $e 20230203 $i 1941-3084 $m Circulation. Arrhythmia and electrophysiology $n Circ Arrhythm Electrophysiol $x MED00159578
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace